Seproxetine
Подписчиков: 0, рейтинг: 0
| Clinical data | |
|---|---|
| ATC code |
|
| Legal status | |
| Legal status |
|
| Pharmacokinetic data | |
| Elimination half-life | 4–16 days |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| IUPHAR/BPS | |
| DrugBank | |
| ChemSpider | |
| UNII | |
| CompTox Dashboard (EPA) | |
| Chemical and physical data | |
| Formula | C16H16F3NO |
| Molar mass | 295.305 g·mol−1 |
Seproxetine, also known as (S)-norfluoxetine, is a selective serotonin reuptake inhibitor (SSRI). It is the S enantiomer of norfluoxetine, the main active metabolite of the widely used antidepressant fluoxetine; but little is known about its pharmacological actions. Seproxetine was being investigated by Eli Lilly and Company as an antidepressant; however, cardiac side effects were discovered and development was discontinued.
| |||||||||||||||||||||
| |||||||||||||||||||||
|
| |||||||||||||||||||||
| |||||||||||||||||||||
| |||||||||||||||||||||
| 5-HT1AR agonists | |
|---|---|
| GABAAR PAMs |
|
|
Gabapentinoids |
|
| Antidepressants |
|
|
Sympatholytics |
|
| Others | |
| |
|
DAT (DRIs) |
|
||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NET (NRIs) |
|
||||||||||||||
|
SERT (SRIs) |
|
||||||||||||||
| VMATs | |||||||||||||||
| Others |
|
||||||||||||||
| Corporate directors | |
|---|---|
| Products |
|